ESMO 2020 — KRAS-inhibitor sotorasib achieves durable disease control in pretreated NSCLC


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An open-label trial with 59 patients heavily pretreated for NSCLC shows a favorable safety profile for sotorasib and a disease control rate of 88.1%.

Why this matters

  • Preliminary antitumor activity was shown in a phase 1 trial of sotorasib in patients with advanced tumors harboring KRAS p.G12C-mutations.
  • Sotorasib (formerly AMG 510) is a first-in-class, oral specific KRAS p.G12C inhibitor.
  • This mutation is found in 13% of NSCLC cases, and there is currently no approved therapy for these.

Study design

  • The phase 1, multicenter, open-label trial CodeBreaK 100 enrolled 129 patients with various types of cancer.
  • Data were presented for 59 of them (median age, 68 years; 90% smokers) with advanced NSCLC and prior systemic treatment (77.5% 2 or more lines; 47.5% 3 lines of therapy).
  • Median follow-up 11.7 months; 3 discontinuations because of adverse events.
  • Funding: Amgen Inc.

Key results

  • No dose-limiting toxicities or fatalities because of treatment.
  • 18.6% with grade 3 or 4 adverse events.
  • Any tumor shrinkage by week 6: 71.2%.
  • Objective response rate: 32.2%.
  • Disease control rate: 88.1%.
  • Median PFS for all patients: 6.3 months.
  • Median duration of response: 10.9 months.
  • No significant association with expression of either KRAS p.G12C or PD-1.

Limitations

  • Limited dataset at cutoff (June 1, 2020).

Follow all ESMO 2020 coverage on   Univadis .